跳至主要内容
临床试验/NCT04883073
NCT04883073已完成不适用

Impact on Quality of Life by Additional Use of the Digital Health Application "Endo-App" to Standard Therapy: Monocentric, Prospective, Randomised Trial (ELEA)

University Hospital Muenster2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2023年1月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
300
试验地点
2
主要终点
EHP 5

研究概览

简要总结

monocentric randomized controlled trial enrolment of endometriosis patients from certified endometriosis centers. Randomization to control group (no Endo App use) vs intervention group (Endo App use) 12 weeks use / no use of Endo App. Evaluation of quality of life at onset, at 4, 8 and 12 weeks by using endometriosis health profile (EHP) 5 as a global index. Statistical analysis of global index at the end minus global index at onset between control and intervention group.

详细描述

randomized controlled trial enrolment of patients with diagnosed endometriosis 300 patients in total, 150 patients per group, randomization to control group (no Endo App use) vs intervention group (12 weeks Endo App use). The Endo App is a german language certified medical device which can be used to monitor the disease and gives support by providing complementary, multimodal interventions to standard therapy and is commercially available. Purpose of this study is the evaluation of quality of life at onset and then at 4, 8 and 12 weeks by using endometriosis health profile (EHP) 5 as a global index. The secondary endpoints of this study to evaluate are Fatigue symptoms (FSSsurvey), pain- specific self-efficacy (FESS), difficulty in everyday life due to pain (PDI) and emotional wellbeing (DASS- 21)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Legal capacity
  • Living in Germany
  • Adequate german language skills
  • Female biological gender
  • Ages eligible for study ≥ 18 years
  • Medical Diagnosis of endometriosis
  • Diagnosis verification by following documents:
  • Operation Report
  • Histological finding
  • MRI finding
  • Other medical examination documents with endometriosis diagnosis (for example sonography, colonoscopy, cystoscopy)
  • Owning a smartphone and having an internet access
  • Willingness and capability of using the smartphone device and the Endo App
  • Motivation to regularly fill out the questionnaries
  • Owning an e-mail address for App registration
  • Absence of exlusion criteria

排除标准

  • Absence of inclusion criteria
  • Pregnancy existing at survey period
  • Ongoing hormonal fertility treatment or planned treatment within the next 12 weeks (artificial insemination as part of in vitro fertilization, such as IVF or ICSI, hormone injections for fertility treatment)
  • Ongoing or within the next 12 weeks planned rehabilitation or multimodal pain therapy
  • Planned change in hormone therapy (change of active substance, new start or discontinuation of therapy) in the next 12 weeks or change in hormone therapy within the last 8 weeks before the start of the study
  • Endometriosis surgery planned in the next 12 weeks or endometriosis surgery performed within the last 8 weeks prior to study start
  • Previous or existing access to Endo app or current prescription

结局指标

主要结局

EHP 5

时间窗: 12 weeks

Change in Endometriosis Health Profile 5 (minimum value: 0 points, maximum value: 100 points, higher scores mean a worse outcome)

次要结局

  • PDI survey(12 weeks)
  • DASS-21 survey(12 weeks)
  • FSS survey(12 weeks)
  • FESS survey(12 weeks)
  • EHP 5(8 weeks)

研究者

发起方
University Hospital Muenster
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. med. Sebastian Daniel Schäfer

Head of Department of Gynecology

University Hospital Muenster

研究点 (2)

Loading locations...

相似试验